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Adoptive immunotherapy with antigen-specific cytotoxic T lymphocytes (CTLs) has proven effective in
restoring cellular immunity to cytomegalovirus (CMV) and preventing viral reactivation after allogeneic
stem cell transplantation (SCT). In an effort to develop a cost-effective, relatively rapid method of CMV
CTL expansion, we investigated the use of a pool of overlapping CMV peptides. Because the possibility exists
of vaccinating CMV-seronegative donors, and these individuals may have T cell responses predominantly
against IE-1, commercially available peptide mixes for pp65 as well as IE-1 were used to stimulate CTLs
from 10 seropositive donors. Of these 10 donors, 4 responded to pp65 only, 1 did not respond to either
pp65 or IE-1, 4 responded to both pp65 and IE-1, and 1 responded to IE-1 only. These CMV- specific T cells
included a mixture of CD41 and CD81 effectors, and specific cytotoxicity correlated with interferon-g pro-
duction. The costs associated with a 28-day maintenance course of intravenous ganciclovir, cidofovir, foscar-
net, and valganciclovir, as well as the preparation and shipping a single dose of CTLs, were determined. The
price of generating CMV CTLs using this method was comparable to or less expensive than a 28-day main-
tenance course for these agents, not including the costs associated with drug administration, supportive care,
and the treatment of drug-related complications. Considering the relative ease, low cost, and the fact that
CTL administration can result in CMV-specific immune reconstitution, this option should be considered
for patients with CMV reactivation or for prophylaxis in patients at high risk for infection.
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Although most cytomegalovirus (CMV) infections
occurring after allogeneic stem cell transplantation
(SCT) will respond to antiviral medications, the use
of these agents has been associated with myelosuppres-
sion, nephrotoxicity, and impaired immune reconsti-
tution [1,2]. This is particularly problematic for
recipients of T cell–depleted SCT, who are at higher
risk for CMV infection and disease. There have been
several previous reports on treatment with CMV-
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1156specific cytotoxic T lymphocytes (CTLs) after SCT,
resulting in cellular immune reconstitution and sup-
pression of viremia [3-5]. Methods for growing these
CTLs include the use of genetically modified anti-
gen-presenting cells (APCs) to achieve CMV pp65 ex-
pression and the pulsing of APCs with CMV peptides
or viral lysates [6,7]. Each of these strategies has intrin-
sic shortcomings. Genetic manipulation of APCs will
result in a natural processing and presentation of
CMV antigens but is complicated by regulatory issues,
high costs, and the time required to qualify viral super-
natants and cell therapy products. Depending on the
vector and APC used, gene therapy approaches add
varying amounts of time for transduction and qualifi-
cation of APCs, which may be problematic when
CTLs are urgently needed [8]. Approaches using
individual peptides are limited by our incomplete
knowledge of HLA-restricted CMV pp65 epitopes,
and CMV T cells expanded using viral lysate may be
predominantly CD41 [4]. Other methods may be
limited by the cost of isolating CTLs and the need
for specialized equipment, such as selecting CTLs
Biol Blood Marrow Transplant 14:1156-1162, 2008 1157CMV pp65 and IE/CTL for Immunotherapybased on cytokine production [9], which may preclude
widespread implementation. To date, the use of CMV
CTLs for treatment or prophylaxis of CMV infection
is not routine, and virus-specific immunotherapy is
offered at only a few centers that have this as a research
interest.
The use of virus-specific CTLs has several poten-
tial benefits, including earlier immune reconstitution
and avoidance of drug-related complications. Consid-
ering the costs of antiviral medications, drug adminis-
tration, and monitoring and treating complications,
the infusion of CMV CTLs may be more cost-effective
and directly beneficial to patients. Limitations to
immunotherapy strategies targeting a single CMV
protein include the fact that in some donors, dominant
immune responses may be directed against antigens
not used in CTL preparation. CMV pp65 is an impor-
tant target for CMV-specific CTLs, given the fact that
70% to 90% of all CTLs recognizing pp65 epitopes
[10]. Other reports indicate that IE-1–specific T cells
also are important in conferring protective immunity
to this virus [11,12], including in patients posttrans-
plantation. In addition, IE-1–specific immune re-
sponses are stronger and sustained over a longer
period after vaccination with the Towne strain of
CMV [13], affecting situations in which CTLs are ex-
panded from vaccinated donors. Although to date the
major focus in adoptive immunotherapy for CMV
has been on pp65-specific immune reconstitution, we
decided to investigate whether CTLs with broader
antigenic specificity can be generated and, if so,
whether the costs associated with cell production can
justify the routine use of cellular immunotherapy for
CMV. In this work, we demonstrate that CMV pp65
and IE-1–specific CTLs can be reliably expanded
from most normal donors, and that infusing these
CTLs can be a cost-effective strategy for treating
patients with CMV reactivation.
METHODS
Cell Culture
Donor blood specimens were collected under
a protocol approved by the Penn State Hershey Med-
ical Center Human Subject Protection Office. Human
leukocyte antigen (HLA) testing was performed sero-
logically for HLA-A, -B, and -DR at the Penn State
Hershey Histocompatibility Laboratory. Between 60
and 80 mL of peripheral blood was collected from
each donors, and peripheral blood mononuclear cells
(PBMCs) were isolated by Ficoll-Hypaque density
gradient centrifugation. Between 50 and 100  106
PBMCs were placed in 15 mL of RPMI (Gibco,
Chicago, IL) with 10% fetal bovine serum (FBS;
Hyclone, Logan, UT) for 1 hour in T150 flasks
(Corning, Corning, NY). Nonadherent peripheralblood lymphocytes (PBLs) were removed and resus-
pended at 2  106/mL in RPMI 1640/10% FBS, and
adherent cells were removed with a cell scraper (Corn-
ing). These adherent cells were then washed in RPMI
1640 and placed at 10  106 in 0.5 mL of RPMI in
50-mL conical centrifuge tubes, then pulsed with
either CMV pp65, IE-1, or both peptides simulta-
neously. The CMV pp65 and IE-1 peptide mixes
(JPT Peptide Technologies, Berlin) consisted of 138
and 120 overlapping 15mers, respectively. Each
peptide were suspended in 40 mL of DMSO (Sigma
Aldrich, St. Louis, MO) in accordance with the manu-
facturer’s instructions. Then 3 mL (0.7 mg/mL) of the
peptide suspension was added to 10 to 20 106 adher-
ent cells, and the capped centrifuge tubes were incu-
bated at room temperature for 2 hours, then washed/
centrifuged in RPMI 1640 3 times. PBLs were plated
with peptide-pulsed adherent cells at a responder:sti-
mulator ratio of 10:1 in 24-well plates (Corning), 2
mL per well. CTLs resulting from this method were
analyzed by chromium release assays and flow cytom-
etry for intracellular cytokine production.
Chromium Release Assays
Targets for chromium release assays (CRAs) in-
cluded autologous and allogeneic B cell blasts (BBs;
used as a negative control) and BBs pulsed with the
pp65 or IE-1 peptide mixes. To determine whether
these effector cells recognized naturally processed
and presented pp65 and IE-1 epitopes, we also infected
BBs with vaccinia encoding pp65 and IE-1 (vacc-pp65,
provided by Dr William Britt, University of Alabama
Birmingham, and vacc-IE-1, provided by Dr Don
Diamond, City of Hope). BBs were cultured from
donor PBMCs as described previously [14]. Targets
were labeled overnight with 51Cr (100 mCi/106 cells;
PerkinElmer Life and Analytical Science, Boston,
MA), washed in PBS, and dispensed in triplicate into
96-well V-bottom plates (ICN, Costa Mesa, CA) at 4
 103 cells/well, as described previously [6]. CTLs
were added at a responder:target ratio of 10:1, and
after pelleting and incubation for 4 hours, the superna-
tant was analyzed in a gamma counter. Spontaneous
and total releases for each target were used to calculate
percent specific release by the following formula:
% specific release5 (experimental cpm2 spontaneous
cpm)/ (total cpm 2 spontaneous cpm).
Intracellular Cytokine Staining
Flow cytometry for interferon (IFN)-g produc-
tion was performed with a FACScan (BD Biosciences,
San Jose, CA) to detect pp65 and IE-1 -specific T
cells. Multiple-color staining of immunophenotypic
markers, both surface and intracellular, was per-
formed as described previously [15]. Surface markers
of CTLs were determined by staining with directly
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CD3, CD4, CD8, and CD56 (BD Biosciences). Cul-
tured T cells were incubated with equal numbers of
stimulators, including autologous BBs pulsed with
pp65 and IE-1 overlapping peptides, autologous and
allogeneic BBs in RPMI 1640 with 10% FCS, and
in the presence of 10 mg/ml brefeldin A (Sigma) at
37

C for 5 hours. After incubation in FACS permea-
bilization buffer (BD Biosciences) for 10 minutes,
cells were aliquoted and stained with the following la-
beled antibodies: CD4-FITC, CD8-peridinin chloro-
phyll protein, and IFN-g APC (BD Biosciences).
RESULTS
To determine whether CMV and IE-1–specific
CTL could be regularly expanded from normal do-
nors, we stimulated PBLs with a peptide mix derived
from IE-1 and pp65 simultaneously. Immunopheno-
typing showed that the most of the cells were CD31,
with a mixture of CD41 and CD81 effector cells also
present, as described in Table 1. The cytotoxicity
data (Figure 1) revealed a lack of autoreactivity or
alloreactivity in these CTLs. Of the 10 donors tested,
4 had cytotoxicity to targets expressing both antigens,
4 had pp65-specific cytotoxicity only, 1 had IE-1 cyto-
toxicity only, and 1 responded to neither antigen. CRA
data on CTLs cultured separately with either pp65 or
IE-1 peptide-pulsed monocytes or with both peptide
mixes combined show that the simultaneous use of
these peptides did not compromise cytotoxicity in
most donors (Table 2). To confirm that these CTLs
recognized naturally processed pp65 and IE-1 epi-
topes, CRA also was performed using BBs infected
with vaccinia encoding either pp65 or IE-1. The re-
sults, shown in Figure 2, indicate similar cytotoxicity
against vaccinia pp65 and IE-1–infected BBs as was
seen from the use of peptides, demonstrating that these
CTLs recognized naturally processed and presented
epitopes of both antigens.
Figure 3 illustrates cytokine production by 3 of our
donors, 2 donors with cytotoxicity and cytokine
production to only 1 of the antigens and 1 donor
Table 1. Phenotype of CTLs stimulated with combined pp65
and IE1 (%)
CD3 CD4 CD8 CD56
Donor 1 89 32 53 0.9
Donor 2 95 28 65 1.5
Donor 3 90 51 36 1.4
Donor 4 90 50 38 0.7
Donor 5 86 62 22 1.8
Donor 6 88 42 45 0.6
Donor 7 89 57 30 1
Donor 8 83 54 29 1
Donor 9 97 38 53 8.2
Donor 10 81 32 40 3with IFN-g production and cytotoxicity to both anti-
gens. In general, the presence of cytotoxicity for either
pp65 or IE-1 was correlated with CD41 and CD81 T
cells producing IFN-g in response to these antigens, as
shown in Table 3. These donors had diverse HLA
backgrounds and varying levels of response to these
antigens. Donor 1 had IE-1–specific cytotoxicity and
CD41 and CD81 cells producing IFN-g in response
to this antigen. This donor lacked pp65-specific cyto-
toxicity as well as CD81 IFN-g–specific T cells, but
0.6% of the cells were IFN-g producing CD41
pp65-specific T cells. Donor 3 had IFN-g producing
CD81 T cells specific for IE-1 but lacked significant
cytotoxicity to this antigen. Donor 8, who was
CMV-seropositive but lacked cytotoxicity to either
antigen, did not have significant levels of IFN-g–pro-
ducing T cells to pp65 or IE-1. Therefore, although
there seems to be a close correlation between IFN-g
production and cytotoxicity, as expected, some donors
without cytotoxicity may have IFN-g production in
response to a specific antigen.
All CTL were cultured for 10 days, with a mean 1.8
6 0.7-fold increase (range, 1.1 to 2.5) in the number of
cells seen at the end of the culture period. Therefore,
for a typical adult patient weighing 70 kg, a 100-mL
blood draw from the stem cell donor permitted a cell
Figure 1. Cytotoxicity of CTLs. PBMCswere pulsed with pooled CMV
pp65 and IE-1 peptides and incubated with PBLs from 10 healthy CMV-
seropositive donors. Targets included autologous BBs, BBs pulsed with
pp65 and IE-1 overlapping peptides, and allogeneic BBs.
Table 2. Cytotoxicity of CTLs stimulated with pp65, IE-1
alone, and combined pp65 and IE-1 (%)
Mixed CTL pp65 + IE-1
CTL pp65 CTL IE-1 pp65 IE-1
Donor 1 8 60 6 66
Donor 2 69 50 54 41
Donor 3 37 4 24 12
Donor 4 47 66 63 59
Donor 5 50 37 62 30
Donor 6 45 8 51 8
Donor 7 46 5 41 6
Donor 8 -1 -2 -3 -2
Donor 9 53 69 31 56
Donor 10 36 -1 31 3
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onstrated that CTL doses as low as 1  105 cells/kg
could result in CMV-specific immune reconstitution,
although 2 of their 14 CTL recipients required a
second infusion for subsequent CMV reactivation.
Therefore, a cell dose of 2 to 5  105 CD31 CTLs/kg
should be adequate for most patients. We compared
the costs of preparing and shipping a single dose of 5
 105 CD31 CTLs/kg (for a 70-kg patient) with the
costs of maintenance therapy with antiviral agents
(cidofovir, ganciclovir, valganciclovir, and foscarnet);
the data are presented in Table 4. This cost analysis
did not take into account the costs of laboratory mon-
itoring, drug administration, and medications or fluids
to treat or prevent complications. From the data, it
appears that the costs of preparing, qualifying, and
shipping CMV CTLs using our proposed method
would be comparable to or less expensive than average
wholesale prices for maintenance courses of these
antiviral agents.
DISCUSSION
The decision to administer CMV CTLs must be
based on an understanding of the risks associated
with CMV infection; the time frame, feasibility, and
cost of CTL culture; as well as the risks associated
with administering CTLs. The method that we
used to generate CMV-specific CTLs is simple and
bypasses the requirement for gene therapy or the use
of other techniques that may be available at only
a few transplantation centers. Our method also is less
expensive than other methods of CTL selection,
such as cytokine capture. Because of the use of special-
ized reagents and labware, the cost of cytokine capture
(including quality assurance testing of the final prod-
uct) is more than threefold greater than that of our
method, not including the expense of a cell selection
Figure 2. Cytotoxicity of CMV CTLs. PBLs were stimulated with
autologous monocytes pulsed with pp65 and IE-1 overlapping peptides.
Specific cytotoxicity was measured using BBs infected with either vac-
cinia encoding pp65 or IE-1 (vvp65, vvIE1), as well as BBs pulsed with
either peptidemix. Autologous and allogeneic BBs were used as negative
controls.device. Considering the relatively low cost, feasibility,
and low risk for graft-versus-host disease (GVHD),
cellular immunotherapy for CMV could be considered
a reasonable option either at the time of reactivation or
as prophylaxis in high-risk patients. As the cost analysis
demonstrates, the cost of CTL preparation does not
differ significantly from that of standard courses of
antivirals, and the latter may need to be used over a
prolonged period if viremia persists or recurs. More-
over, antiviral drugs can cause multiple side effects,
most commonly nephrotoxicity and myelosuppres-
sion. These toxicities are compounded by the fact
that many SCT recipients may have cytopenias, and
most are receiving other nephrotoxic agents. The fre-
quency of neutropenia ranges from 40% to 60% in
SCT patients who receive ganciclovir [16,17]. More-
over, the use of ganciclovir has been associated with in-
creases in bacterial sepsis and invasive fungal infections
[16,18,19] and also has a negative effect on CMV-spe-
cific cellular immune responses as well as lymphocyte
function in general [2]. The use of a second-line agent,
such as foscarnet or cidofovir, can be limited by the
potential for severe nephrotoxicity, necessitating intra-
venous fluid administration and careful monitoring of
hydration and electrolyte status [20]. Intervention with
CMV-specific CTLs not only results in virus-specific
immune reconstitution and prevention of further
viremia, but also could reduce overall patient care
costs.
The primary motivation for expanding IE-1– and
pp65-specific CD41 and CD81T cells simultaneously
is to provide CTLs with reactivity against viral epi-
topes that are relevant for a broad group of patients.
Our work and other studies [21] has revealed a wide
diversity in CD4 and CD8 T cell responses to different
CMV antigens in normal donors. Variability in the rel-
ative numbers of CD4 and CD8 effector cells and
IFN-g production among normal donors could reflect
individual CMV-specific cellular immunity, as well as
differences in HLA background and epitope domi-
nance. These variables will likely result in differences
in the degree of T cell responsiveness to epitopes pre-
sented in the peptide mix, some of which may not be
presented optimally. Previous studies have demon-
strated the importance of CMV-specific CD41 T cells
for achieving long-term immune reconstitution to this
virus [22]. Our findings indicate that both CD41 and
CD81 pp65- and IE-1–specific effector cells were
present after stimulation with these peptide mixes,
and that the ratios of CD4 and CD8 T cells were
well balanced. The patterns of antigen-specific cyto-
toxicity were similar regardless of whether pp65 and
IE-1 CTLs were stimulated separately or simulta-
neously. Although some donors respond to a given
antigen but not to others, some individuals demon-
strate IFN-g responses to an antigen but lack activity
in CRA. It is possible that with further courses of
1160 Biol Blood Marrow Transplant 14:1156-1162, 2008L. Bao et al.Figure 3. IFN-g production of T cells. PBMCs were pulsed with pooled CMV pp65 peptides and IE-1 peptides and incubated with nonadherent PBLs.
IFN-g producing T cells specific for these CMV peptides were analyzed at day 10 of culture by intracellular staining. A, CD81 T cell response to CMV
pooled peptides. B, CD41 T cell response to the CMV peptides.
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Response to pp65 (%) Response to IE-1 (%) HLA typing
CD4 CD8 CD4 CD8 HLA- A HLA- B HLA-DR
Donor 1 0.59 0.09 0.38 23 11 38, 54 04, 08
Donor 2 0.98 19.08 0.39 3.96 02, 03 07, 55 04, 14
Donor 3 0.81 2.42 0.12 0.44 11, 24 07, 51 01, 03
Donor 4 2.2 5.3 0.36 6 02 27, 41 01, 08
Donor 5 10.86 7.3 0.8 0.78 02, 26 41, 44 08, 11
Donor 6 0.48 5.31 0.26 0.91 02, 26 46, 48 08
Donor 7 10.4 5.25 0.26 0.02 01, 02 13, 60 07, 11
Donor 8 0.17 0.04 0.15 0.05 02, 25 18, 60 01, 04
Donor 9 16.48 1.82 1.53 21.61 11, 24 54, 60 14, 15
Donor 10 0.71 2.81 0.13 0.19 11, 31 35, 60 04, 09stimulation, these donors could develop cytotoxicity.
Further study is needed to determine the role of
cytokine-producing effector cells for donors who
lack cytotoxicity to a specific antigen.
Although CMV pp65 has been shown to be the im-
munodominant CMV antigen, IE-1–specific immu-
nity also is important in protecting against CMV
[11]. In organ transplant recipients, Bunde et al. [23]
demonstrated that having high frequencies of IE-1–
specific T cells in the early posttransplantation course
was protective against developing CMV disease. Khan
et al. [11] reported that IE-1–specific T cells increase
over time postinfection and may be effective in pre-
venting low-level viral reactivation after an acute infec-
tion. Other studies have shown that a situation of
a higher proportion of pp65-specific T cells than IE-
1–specific T cells makes IFN-g and tumor necrosis
factor-a and has greater cytotoxicity in SCT and organ
transplant recipients [24]. Studies are currently under-
way at our center and others examining the use of
CMV vaccines in seronegative stem cell donors. One
such vaccine consists of the Towne strain of CMV,
which has been shown to result in higher levels of
IFN-g–producing CD81 T cells to IE-1 compared
with pp65 [13]. Whereas pp65 responses decrease
over time in these vaccine recipients, IE-1 responses
tend to be maintained; thus, CTLs with reactivity to
more than 1 antigen is of potential benefit. Although
priming T cells with CMV lysate could result in cells
Table 4. Cost of Antiviral Agents and CTL
Regimen, for a 70-kg patient, 28 days
Average wholesale
price (USD)*
Ganciclovir, 5 mg/kg/day i.v. 1048.60
Foscarnet, 90 mg/kg/day i.v. 1234.80
Valganciclovir, 15 mg/kg/day p.o. 1915.20
Cidofovir, 5 mg/kg/week every 2 weeks 1657.60
Single infusion of CMV CTLs 1350.00
*These figures include quality assurance testing, cryopreservation, and
shipping of CTLs but do not account for intravenous administration
costs, compounding costs of oral medications, charges for laboratory
monitoring, or costs of medications to treat or prevent drug-related
complications. Drug costs are from Cardinal Health Corporation, April
2008 (http://www.cardinal.com).with a broader range of specificity, this method of
stimulation has been shown to favor CD41 T cell
expansion [4].
An overriding concern with any use of cellular
immunotherapy after allogeneic SCT is the efficacy
of the product and the risks for GVHD, although
this complication generally is not seen with adoptive
immunotherapy using virus-specific CTLs [4,7]. The
cellular products described in this report lack autor-
eactivity or alloreactivity in CRA, and 2 patients who
have received pp65-specific CTL using this method
have not developed GVHD as of the time of this writ-
ing (in press). With selective expansion of CTLs, we
would expect to see a decrease in potentially alloreac-
tive CTLs and an enrichment of CMV CTLs over the
10 days in culture, and the administration of relatively
low cell doses as in our current protocol (2 to 5  105
CD31 CTLs/kg) likely would decrease the risk of
GVHD. Situations in which there is no urgency for
culturing CTLs (as when cells are cultured prospec-
tively for prophylaxis) would allow for longer culture
times, further reducing the risk of GVHD. The mini-
mal cell dose needed for immune reconstitution using
CMV-specific CTLs has not yet been defined; it will
depend on the level of enrichment of virus-specific
cells. MacKinnon et al. [25] reported the use 1  105
CD31 CMV- specific T cells/kg, with no recipients
developing GVHD and most recipients experiencing
no subsequent CMV reactivation. This group also de-
scribed the selection of CTLs based on IFN–g capture
[9], with a mean CMV-reactive T cell dose of 3.4 106
total cells per patient. The administration of lower
doses of CMV-specific T cells in the future would re-
duce the GVHD risk and permit the cryopreservation
of several vials for subsequent infusions, if needed.
The use of both CMV IE-1 and pp65 peptides
covers immunologically relevant CMV antigens for
most individuals, although some donors may not
respond to either antigen after 10 days of culture and
may need subsequent stimulation with these peptides.
For those at high risk for CMV reactivation, prospec-
tively culturing these CTLs from seropositive donors
could be considered, with the CTLs infused either
1162 Biol Blood Marrow Transplant 14:1156-1162, 2008L. Bao et al.prophylactically or at reactivation. With several studies
demonstrating the efficacy of adoptive immunotherapy
with CMV CTLs, and with a practical method
whereby these cells can be expanded, this form of ther-
apy could be considered for more patients, particularly
in light of the high cost and deleterious side effects of
most antiviral agents. It also is possible that CTLs
with specificity to other viral, fungal, or tumor antigens
could be cultured concurrently using this method, as
has been described previously using gene therapy ap-
proaches. We will be implementing this new strategy
to stimulate donor-derived IE-1 and pp65 CTLs for
SCT patients with CMV reactivation, including those
with donors who have received a CMV vaccine.
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